[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fPqIMVRQZbhBXkVYiGB27RAqnm1D57pxpAfccEPHZfE8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":75,"rows":82},"University Hospital Heidelberg",[4],175,false,53,5,117300,12,149,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Ischemic Stroke",9,{"name":18,"count":19},"Coronary Artery Disease",7,{"name":21,"count":22},"Cancer",6,{"name":24,"count":9},"Atrial Fibrillation",{"name":26,"count":27},"Exercise",3,{"name":29,"count":27},"Acute Myeloid Leukemia",{"name":31,"count":27},"Non-small Cell Lung Cancer",{"name":33,"count":27},"Brain Metastases",[35,40,45,50,55,60,65,70],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04865250","Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin\u002FNab Paclitaxel in Resectable Non-squamous NSCLC","2024-11-30","Atezolizumab 1200 mg abs day 1 q22",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03838042","INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies","2026-06-30","Nivolumab and Entinostat",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03676504","Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR","2026-12-31","CD19.CAR T Cells",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05946772","Cyclosporine In Takotsubo Syndrome","2027-02","Cyclosporine A",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06456359","Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor","2027-10","Signifor",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06408116","Predicting Esophageal Cancer Borders Using PET-Imaging","2028-01","Chemotherapy",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06243393","Sacituzumab Govitecan in Metastatic Colorectal Cancer","2028-08-01","Sacituzumab Govitecan",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05331521","A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).","2033-03-31","CETEG",[76,77,78,79,80,81],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[83,109,127,149,167,190,212,241,259,277,300,324,347,374,401,419,437,464,482,500,543,585,610,636,654,676,694,712,730,748,766,784,809,834,859,877,902,926,951,978],{"intervention":69,"totalTrials":84,"cells":85},1,{"EARLY_PHASE1":86,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":105,"NA":107},{"trials":87,"activeCount":88},[],0,{"trials":90,"activeCount":88},[],{"trials":92,"activeCount":88},[],{"trials":94,"activeCount":84,"soonestReadout":68},[95],{"nctId":66,"briefTitle":67,"status":96,"phases":97,"primaryCompletion":68,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":103},"RECRUITING",[78,79],"2029-02-01","2024-04-19",80,[102],"Metastatic Colorectal Cancer",[69,104],"Physicians Choice (PhC).",{"trials":106,"activeCount":88},[],{"trials":108,"activeCount":88},[],{"intervention":104,"totalTrials":84,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":123,"NA":125},{"trials":112,"activeCount":88},[],{"trials":114,"activeCount":88},[],{"trials":116,"activeCount":88},[],{"trials":118,"activeCount":84,"soonestReadout":68},[119],{"nctId":66,"briefTitle":67,"status":96,"phases":120,"primaryCompletion":68,"completion":98,"start":99,"enrollment":100,"conditions":121,"interventions":122},[78,79],[102],[69,104],{"trials":124,"activeCount":88},[],{"trials":126,"activeCount":88},[],{"intervention":74,"totalTrials":84,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":145,"NA":147},{"trials":130,"activeCount":88},[],{"trials":132,"activeCount":88},[],{"trials":134,"activeCount":88},[],{"trials":136,"activeCount":84,"soonestReadout":73},[137],{"nctId":71,"briefTitle":72,"status":96,"phases":138,"primaryCompletion":73,"completion":73,"start":139,"enrollment":140,"conditions":141,"interventions":143},[79],"2021-04-07",406,[142],"Oligodendroglioma",[74,144],"PCV",{"trials":146,"activeCount":88},[],{"trials":148,"activeCount":88},[],{"intervention":144,"totalTrials":84,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":163,"NA":165},{"trials":152,"activeCount":88},[],{"trials":154,"activeCount":88},[],{"trials":156,"activeCount":88},[],{"trials":158,"activeCount":84,"soonestReadout":73},[159],{"nctId":71,"briefTitle":72,"status":96,"phases":160,"primaryCompletion":73,"completion":73,"start":139,"enrollment":140,"conditions":161,"interventions":162},[79],[142],[74,144],{"trials":164,"activeCount":88},[],{"trials":166,"activeCount":88},[],{"intervention":64,"totalTrials":84,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":170,"activeCount":88},[],{"trials":172,"activeCount":88},[],{"trials":174,"activeCount":84,"soonestReadout":63},[175],{"nctId":61,"briefTitle":62,"status":96,"phases":176,"primaryCompletion":63,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":183},[78],"2028-04","2024-03-01",30,[181,182],"Esophagus Cancer, Stage I","Esophagus Cancer, Stage II",[64],{"trials":185,"activeCount":88},[],{"trials":187,"activeCount":88},[],{"trials":189,"activeCount":88},[],{"intervention":54,"totalTrials":84,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":206,"PHASE4":208,"NA":210},{"trials":193,"activeCount":88},[],{"trials":195,"activeCount":88},[],{"trials":197,"activeCount":84,"soonestReadout":53},[198],{"nctId":51,"briefTitle":52,"status":96,"phases":199,"primaryCompletion":53,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":205},[78],"2028-02","2025-02-01",204,[204],"Takotsubo Cardiomyopathy",[54],{"trials":207,"activeCount":88},[],{"trials":209,"activeCount":88},[],{"trials":211,"activeCount":88},[],{"intervention":49,"totalTrials":84,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":235,"PHASE4":237,"NA":239},{"trials":215,"activeCount":88},[],{"trials":217,"activeCount":88},[],{"trials":219,"activeCount":84,"soonestReadout":48},[220],{"nctId":46,"briefTitle":47,"status":96,"phases":221,"primaryCompletion":48,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":232},[77,78],"2027-12-31","2018-09-07",68,[226,227,228,229,230,231],"Acute Lymphoblastic Leukemia, Adult","Acute Lymphoblastic Leukemia, Pediatric","Chronic Lymphocytic Leukemia","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma",[49,233,234],"Fludarabine","Cyclophosphamide",{"trials":236,"activeCount":88},[],{"trials":238,"activeCount":88},[],{"trials":240,"activeCount":88},[],{"intervention":233,"totalTrials":84,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":244,"activeCount":88},[],{"trials":246,"activeCount":88},[],{"trials":248,"activeCount":84,"soonestReadout":48},[249],{"nctId":46,"briefTitle":47,"status":96,"phases":250,"primaryCompletion":48,"completion":222,"start":223,"enrollment":224,"conditions":251,"interventions":252},[77,78],[226,227,228,229,230,231],[49,233,234],{"trials":254,"activeCount":88},[],{"trials":256,"activeCount":88},[],{"trials":258,"activeCount":88},[],{"intervention":234,"totalTrials":84,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":262,"activeCount":88},[],{"trials":264,"activeCount":88},[],{"trials":266,"activeCount":84,"soonestReadout":48},[267],{"nctId":46,"briefTitle":47,"status":96,"phases":268,"primaryCompletion":48,"completion":222,"start":223,"enrollment":224,"conditions":269,"interventions":270},[77,78],[226,227,228,229,230,231],[49,233,234],{"trials":272,"activeCount":88},[],{"trials":274,"activeCount":88},[],{"trials":276,"activeCount":88},[],{"intervention":59,"totalTrials":84,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":280,"activeCount":88},[],{"trials":282,"activeCount":88},[],{"trials":284,"activeCount":84,"soonestReadout":58},[285],{"nctId":56,"briefTitle":57,"status":96,"phases":286,"primaryCompletion":58,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":293},[78],"2028-10","2024-12-19",28,[291,292],"Desmoplastic Small Round Cell Tumor","Synovial Sarcoma",[59],{"trials":295,"activeCount":88},[],{"trials":297,"activeCount":88},[],{"trials":299,"activeCount":88},[],{"intervention":39,"totalTrials":84,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":318,"PHASE4":320,"NA":322},{"trials":303,"activeCount":88},[],{"trials":305,"activeCount":88},[],{"trials":307,"activeCount":84,"soonestReadout":38},[308],{"nctId":36,"briefTitle":37,"status":96,"phases":309,"primaryCompletion":38,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":317},[78],"2026-12-30","2021-01-07",20,[314,315,316],"NSCLC Stage II","NSCLC, Stage IIIA","NSCLC Stage IIIB",[39],{"trials":319,"activeCount":88},[],{"trials":321,"activeCount":88},[],{"trials":323,"activeCount":88},[],{"intervention":44,"totalTrials":84,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":341,"PHASE4":343,"NA":345},{"trials":327,"activeCount":88},[],{"trials":329,"activeCount":88},[],{"trials":331,"activeCount":84,"soonestReadout":43},[332],{"nctId":41,"briefTitle":42,"status":96,"phases":333,"primaryCompletion":43,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":340},[77,78],"2027-06-30","2020-05-26",91,[338,339],"CNS Tumor","Solid Tumor",[44],{"trials":342,"activeCount":88},[],{"trials":344,"activeCount":88},[],{"trials":346,"activeCount":88},[],{"intervention":348,"totalTrials":84,"cells":349},"rituximab",{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":370,"NA":372},{"trials":351,"activeCount":88},[],{"trials":353,"activeCount":88},[],{"trials":355,"activeCount":88},[],{"trials":357,"activeCount":88},[358],{"nctId":359,"briefTitle":360,"status":361,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT01933711","Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma","UNKNOWN",[79],"2016-12","2018-12","2002-07",328,[368],"CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma",[348],{"trials":371,"activeCount":88},[],{"trials":373,"activeCount":88},[],{"intervention":375,"totalTrials":84,"cells":376},"Quizartinib",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":397,"NA":399},{"trials":378,"activeCount":88},[],{"trials":380,"activeCount":88},[],{"trials":382,"activeCount":88},[],{"trials":384,"activeCount":88},[385],{"nctId":386,"briefTitle":387,"status":388,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":88,"conditions":393,"interventions":394},"NCT04676243","Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","WITHDRAWN",[79],"2025-05","2025-12","2022-05",[29],[375,395,396],"Treatment according to Physician's Choice","Standard of Care Chemotherapy",{"trials":398,"activeCount":88},[],{"trials":400,"activeCount":88},[],{"intervention":395,"totalTrials":84,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":415,"NA":417},{"trials":404,"activeCount":88},[],{"trials":406,"activeCount":88},[],{"trials":408,"activeCount":88},[],{"trials":410,"activeCount":88},[411],{"nctId":386,"briefTitle":387,"status":388,"phases":412,"primaryCompletion":390,"completion":391,"start":392,"enrollment":88,"conditions":413,"interventions":414},[79],[29],[375,395,396],{"trials":416,"activeCount":88},[],{"trials":418,"activeCount":88},[],{"intervention":396,"totalTrials":84,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":433,"NA":435},{"trials":422,"activeCount":88},[],{"trials":424,"activeCount":88},[],{"trials":426,"activeCount":88},[],{"trials":428,"activeCount":88},[429],{"nctId":386,"briefTitle":387,"status":388,"phases":430,"primaryCompletion":390,"completion":391,"start":392,"enrollment":88,"conditions":431,"interventions":432},[79],[29],[375,395,396],{"trials":434,"activeCount":88},[],{"trials":436,"activeCount":88},[],{"intervention":438,"totalTrials":84,"cells":439},"Gemtuzumab Ozogamicin 147",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":460,"NA":462},{"trials":441,"activeCount":88},[],{"trials":443,"activeCount":88},[],{"trials":445,"activeCount":88},[],{"trials":447,"activeCount":88},[448],{"nctId":449,"briefTitle":450,"status":451,"phases":452,"primaryCompletion":453,"completion":454,"start":455,"enrollment":289,"conditions":456,"interventions":457},"NCT04093505","Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)","TERMINATED",[79],"2022-06-15","2022-06-23","2021-04-01",[29],[438,458,459],"Gemtuzumab Ozogamicin 1","Glasdegib",{"trials":461,"activeCount":88},[],{"trials":463,"activeCount":88},[],{"intervention":458,"totalTrials":84,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":478,"NA":480},{"trials":467,"activeCount":88},[],{"trials":469,"activeCount":88},[],{"trials":471,"activeCount":88},[],{"trials":473,"activeCount":88},[474],{"nctId":449,"briefTitle":450,"status":451,"phases":475,"primaryCompletion":453,"completion":454,"start":455,"enrollment":289,"conditions":476,"interventions":477},[79],[29],[438,458,459],{"trials":479,"activeCount":88},[],{"trials":481,"activeCount":88},[],{"intervention":459,"totalTrials":84,"cells":483},{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":496,"NA":498},{"trials":485,"activeCount":88},[],{"trials":487,"activeCount":88},[],{"trials":489,"activeCount":88},[],{"trials":491,"activeCount":88},[492],{"nctId":449,"briefTitle":450,"status":451,"phases":493,"primaryCompletion":453,"completion":454,"start":455,"enrollment":289,"conditions":494,"interventions":495},[79],[29],[438,458,459],{"trials":497,"activeCount":88},[],{"trials":499,"activeCount":88},[],{"intervention":501,"totalTrials":27,"cells":502},"Cold crystalloid infusions, 0.9%NaCl or Ringer's solution",{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":504,"activeCount":88},[],{"trials":506,"activeCount":88},[],{"trials":508,"activeCount":88},[509,519,528],{"nctId":510,"briefTitle":511,"status":361,"phases":512,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT01669408","Prehospital COOLing 1 (PreCOOL 1)",[78],"2013-09","2012-09",40,[517],"Stroke",[501],{"nctId":520,"briefTitle":521,"status":361,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":312,"conditions":525,"interventions":527},"NCT01584167","A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Flex.Pads (iCOOL 2)",[78],"2013-12","2012-01",[15,526],"Hemorrhagic Stroke",[501],{"nctId":529,"briefTitle":530,"status":531,"phases":532,"primaryCompletion":533,"start":534,"enrollment":312,"conditions":535,"interventions":536},"NCT01573117","A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill (iCOOL 1)","COMPLETED",[78],"2011-11","2010-09",[15,526],[501],{"trials":538,"activeCount":88},[],{"trials":540,"activeCount":88},[],{"trials":542,"activeCount":88},[],{"intervention":544,"totalTrials":545,"cells":546},"Palbociclib",2,{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":548,"activeCount":88},[],{"trials":550,"activeCount":88},[],{"trials":552,"activeCount":88},[553,563],{"nctId":554,"briefTitle":555,"status":531,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT03110744","CDK4\u002F6 Inhibition in Locally Advanced\u002FMetastatic Chordoma",[78],"2022-12-22","2017-12-15",43,[561],"Chordoma",[544],{"nctId":564,"briefTitle":565,"status":531,"phases":566,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},"NCT03158389","NCT Neuro Master Match - N²M² (NOA-20)",[77,78],"2023-02-22","2018-05-07",228,[571],"Glioblastoma, Adult",[573,574,575,576,577,578,544],"APG101","Alectinib","Idasanutlin","Atezolizumab","Vismodegib","Temsirolimus",{"trials":580,"activeCount":88},[],{"trials":582,"activeCount":88},[],{"trials":584,"activeCount":88},[],{"intervention":586,"totalTrials":84,"cells":587},"Nivolumab\u002FIpilimumab",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":604,"PHASE4":606,"NA":608},{"trials":589,"activeCount":88},[],{"trials":591,"activeCount":88},[],{"trials":593,"activeCount":88},[594],{"nctId":595,"briefTitle":596,"status":361,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT04131621","Nivolumab\u002FIpilimumab in Second Line CUP-syndrome",[78],"2022-12","2019-12-12",194,[602],"Cancer of Unknown Primary Site",[586],{"trials":605,"activeCount":88},[],{"trials":607,"activeCount":88},[],{"trials":609,"activeCount":88},[],{"intervention":611,"totalTrials":84,"cells":612},"Bortezomib",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":614,"activeCount":88},[],{"trials":616,"activeCount":88},[],{"trials":618,"activeCount":88},[619],{"nctId":620,"briefTitle":621,"status":531,"phases":622,"primaryCompletion":623,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":628},"NCT04173585","TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib",[78],"2023-02-28","2023-03-24","2019-10-22",50,[29],[611,629],"Gemtuzumab Ozogamicin",{"trials":631,"activeCount":88},[],{"trials":633,"activeCount":88},[],{"trials":635,"activeCount":88},[],{"intervention":629,"totalTrials":84,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":639,"activeCount":88},[],{"trials":641,"activeCount":88},[],{"trials":643,"activeCount":88},[644],{"nctId":620,"briefTitle":621,"status":531,"phases":645,"primaryCompletion":623,"completion":624,"start":625,"enrollment":626,"conditions":646,"interventions":647},[78],[29],[611,629],{"trials":649,"activeCount":88},[],{"trials":651,"activeCount":88},[],{"trials":653,"activeCount":88},[],{"intervention":655,"totalTrials":84,"cells":656},"Cold crystalloid infusions, 0.9%NaCl or Ringer's",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":658,"activeCount":88},[],{"trials":660,"activeCount":88},[],{"trials":662,"activeCount":88},[663],{"nctId":664,"briefTitle":665,"status":531,"phases":666,"primaryCompletion":667,"completion":667,"start":524,"enrollment":312,"conditions":668,"interventions":669},"NCT01584180","A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Brain.Pad (iCOOL 3)",[78],"2012-05",[15,526],[655],{"trials":671,"activeCount":88},[],{"trials":673,"activeCount":88},[],{"trials":675,"activeCount":88},[],{"intervention":573,"totalTrials":84,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":679,"activeCount":88},[],{"trials":681,"activeCount":88},[],{"trials":683,"activeCount":88},[684],{"nctId":564,"briefTitle":565,"status":531,"phases":685,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":686,"interventions":687},[77,78],[571],[573,574,575,576,577,578,544],{"trials":689,"activeCount":88},[],{"trials":691,"activeCount":88},[],{"trials":693,"activeCount":88},[],{"intervention":574,"totalTrials":84,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":706,"PHASE4":708,"NA":710},{"trials":697,"activeCount":88},[],{"trials":699,"activeCount":88},[],{"trials":701,"activeCount":88},[702],{"nctId":564,"briefTitle":565,"status":531,"phases":703,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":704,"interventions":705},[77,78],[571],[573,574,575,576,577,578,544],{"trials":707,"activeCount":88},[],{"trials":709,"activeCount":88},[],{"trials":711,"activeCount":88},[],{"intervention":575,"totalTrials":84,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":724,"PHASE4":726,"NA":728},{"trials":715,"activeCount":88},[],{"trials":717,"activeCount":88},[],{"trials":719,"activeCount":88},[720],{"nctId":564,"briefTitle":565,"status":531,"phases":721,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":722,"interventions":723},[77,78],[571],[573,574,575,576,577,578,544],{"trials":725,"activeCount":88},[],{"trials":727,"activeCount":88},[],{"trials":729,"activeCount":88},[],{"intervention":576,"totalTrials":84,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":733,"activeCount":88},[],{"trials":735,"activeCount":88},[],{"trials":737,"activeCount":88},[738],{"nctId":564,"briefTitle":565,"status":531,"phases":739,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":740,"interventions":741},[77,78],[571],[573,574,575,576,577,578,544],{"trials":743,"activeCount":88},[],{"trials":745,"activeCount":88},[],{"trials":747,"activeCount":88},[],{"intervention":577,"totalTrials":84,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":751,"activeCount":88},[],{"trials":753,"activeCount":88},[],{"trials":755,"activeCount":88},[756],{"nctId":564,"briefTitle":565,"status":531,"phases":757,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":758,"interventions":759},[77,78],[571],[573,574,575,576,577,578,544],{"trials":761,"activeCount":88},[],{"trials":763,"activeCount":88},[],{"trials":765,"activeCount":88},[],{"intervention":578,"totalTrials":84,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":769,"activeCount":88},[],{"trials":771,"activeCount":88},[],{"trials":773,"activeCount":88},[774],{"nctId":564,"briefTitle":565,"status":531,"phases":775,"primaryCompletion":567,"completion":567,"start":568,"enrollment":569,"conditions":776,"interventions":777},[77,78],[571],[573,574,575,576,577,578,544],{"trials":779,"activeCount":88},[],{"trials":781,"activeCount":88},[],{"trials":783,"activeCount":88},[],{"intervention":785,"totalTrials":84,"cells":786},"Bendamustine, Bortezomib, Prednisone",{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":788,"activeCount":88},[],{"trials":790,"activeCount":88},[],{"trials":792,"activeCount":88},[793],{"nctId":794,"briefTitle":795,"status":531,"phases":796,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":802},"NCT02237261","Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma",[78],"2018-10","2014-11",46,[801],"Multiple Myeloma",[785],{"trials":804,"activeCount":88},[],{"trials":806,"activeCount":88},[],{"trials":808,"activeCount":88},[],{"intervention":810,"totalTrials":84,"cells":811},"Nivolumab plus Ipilimumab plus Maraviroc",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":832},{"trials":813,"activeCount":88},[],{"trials":815,"activeCount":88},[816],{"nctId":817,"briefTitle":818,"status":531,"phases":819,"primaryCompletion":820,"completion":820,"start":821,"enrollment":626,"conditions":822,"interventions":825},"NCT04721301","Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial",[77],"2023-03-15","2017-01-15",[823,824],"Colorectal Cancer Metastatic","Pancreatic Cancer Metastatic",[810],{"trials":827,"activeCount":88},[],{"trials":829,"activeCount":88},[],{"trials":831,"activeCount":88},[],{"trials":833,"activeCount":88},[],{"intervention":835,"totalTrials":84,"cells":836},"Pembrolizumab",{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":851,"PHASE3":853,"PHASE4":855,"NA":857},{"trials":838,"activeCount":88},[],{"trials":840,"activeCount":88},[841],{"nctId":842,"briefTitle":843,"status":531,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":312,"conditions":847,"interventions":849},"NCT03274804","Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC",[77],"2020-03-01","2018-04-01",[102,848],"MSS",[835,850],"Maraviroc",{"trials":852,"activeCount":88},[],{"trials":854,"activeCount":88},[],{"trials":856,"activeCount":88},[],{"trials":858,"activeCount":88},[],{"intervention":850,"totalTrials":84,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":862,"activeCount":88},[],{"trials":864,"activeCount":88},[865],{"nctId":842,"briefTitle":843,"status":531,"phases":866,"primaryCompletion":845,"completion":845,"start":846,"enrollment":312,"conditions":867,"interventions":868},[77],[102,848],[835,850],{"trials":870,"activeCount":88},[],{"trials":872,"activeCount":88},[],{"trials":874,"activeCount":88},[],{"trials":876,"activeCount":88},[],{"intervention":878,"totalTrials":84,"cells":879},"Dacogen",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":881,"activeCount":88},[],{"trials":883,"activeCount":88},[884],{"nctId":885,"briefTitle":886,"status":451,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":27,"conditions":890,"interventions":893},"NCT04252248","Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage",[77],"2021-06-15","2019-10-11",[891,892],"Head and Neck Cancer","Anogenital Cancer",[878],{"trials":895,"activeCount":88},[],{"trials":897,"activeCount":88},[],{"trials":899,"activeCount":88},[],{"trials":901,"activeCount":88},[],{"intervention":903,"totalTrials":84,"cells":904},"Oxytocin",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":906,"activeCount":88},[],{"trials":908,"activeCount":88},[],{"trials":910,"activeCount":88},[],{"trials":912,"activeCount":88},[],{"trials":914,"activeCount":88},[],{"trials":916,"activeCount":88},[917],{"nctId":918,"briefTitle":919,"status":531,"phases":920,"primaryCompletion":921,"start":922,"conditions":923,"interventions":925},"NCT02689596","Oxytocin and Resting State fMRI",[81],"2015-10","2014-10",[924],"Healthy",[903],{"intervention":927,"totalTrials":84,"cells":928},"Tacrolimus",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":930,"activeCount":88},[],{"trials":932,"activeCount":88},[],{"trials":934,"activeCount":88},[],{"trials":936,"activeCount":88},[],{"trials":938,"activeCount":88},[],{"trials":940,"activeCount":88},[941],{"nctId":942,"briefTitle":943,"status":361,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":950},"NCT04444817","Evaluation of the Impact of Tacrolimus-based Immunosuppression on Heidelberg Liver Transplant Cohort (HDTACRO): Study Protocol for an Investigator Initiated, Non-interventional Prospective Study",[],"2021-12-30","2018-11-22",100,[949],"Liver Transplantation",[927],{"intervention":952,"totalTrials":84,"cells":953},"Physostigmine",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":955,"activeCount":88},[],{"trials":957,"activeCount":88},[],{"trials":959,"activeCount":88},[],{"trials":961,"activeCount":88},[],{"trials":963,"activeCount":88},[],{"trials":965,"activeCount":88},[966],{"nctId":967,"briefTitle":968,"status":531,"phases":969,"primaryCompletion":970,"completion":970,"start":971,"enrollment":312,"conditions":972,"interventions":976},"NCT03013322","Anticholium® Per Se",[81],"2017-02-18","2015-01-28",[973,974,975],"Shock, Septic","Sepsis","Perioperative Period",[952,977],"Isotonic Saline",{"intervention":977,"totalTrials":84,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":981,"activeCount":88},[],{"trials":983,"activeCount":88},[],{"trials":985,"activeCount":88},[],{"trials":987,"activeCount":88},[],{"trials":989,"activeCount":88},[],{"trials":991,"activeCount":88},[992],{"nctId":967,"briefTitle":968,"status":531,"phases":993,"primaryCompletion":970,"completion":970,"start":971,"enrollment":312,"conditions":994,"interventions":995},[81],[973,974,975],[952,977]]